KRT19 is abnormally expressed in various cancers including hepatocellular carcinoma [20], breast cancer [21, 22], colorectal cancer [23], papillary thyroid carcinoma [24], serous ovarian cystadenocarcinoma [25] and et al. KRT19 has been revealed to mediate cell cycle, cancer stem cell reprogramming by interacting with cellular molecules including receptors, adaptors, effectors and kinases. Here, KRT19 is linked to ovarian serous cystadenocarcinoma.